Poor circulation has the potential to deliver a variety of unpleasant consequences — from banal muscle pains to the potential development of gangrene.
“Throughout the world, it is estimated that every 30 seconds a leg is amputated. And 85% of these amputations were the result of a diabetic foot ulcer.” – Foluso A. Fakorede, MD
Amputation might be necessary for as high as 43% of patients diagnosed with Diabetic Foot Ulcer (DFU) within 1-4 years at a cost of thousands of dollars. DFU and its standard treatment results in lower productivity of the patient, reduced quality of life, physical and emotional burden to loved ones and a huge financial cost that can reach tens of thousands of dollars annually on average.
The U.S. has the highest incidence rates for DFU with the highest cost, while the number of patients is expected to keep growing for the foreseeable future.
D’OXYVA® (deoxyhemoglobin vasodilator) achieves consistent and powerful results by significantly improving healing time, reducing long-term pain, and lowering the cost of treatment of this epidemic, while providing a massive return for investors as well.
Circularity Healthcare, LLC is a decade-old, revenue-stage, private company in the final stages of obtaining updated FDA approval for D’OXYVA through expanded pivotal trials with the assistance of most Ivy League colleges, a global clinical research organization (CRO) and a global law firm on its currently approved platform drug and move the product to the U.S. market, which will be its biggest market.
The global diabetic foot ulcer treatment market was valued at over $8.7 billion in 2020 and is predicted to reach $12.3 billion by 2026, rising at a remarkable 7.9% CAGR between 2021 and 2026, according to Facts and Factors.
D’OXYVA® – a patented, world’s first noninvasive, clinically-tested, regenerative transdermal drug delivery product with an FDA-approved platform non-toxic drug is about to disrupt the industry by radically changing the standard of care and become the universal treatment for the epidemic of diabetic wounds or diabetic foot ulcers (DFU).
D’OXYVA’s mechanism of action is unique — life-restoring ultra-purified, FDA-approved, molecular carbon dioxide (CO2) and gentle vapor dissolves across the skin to act as a messenger (gasotransmitter) for significantly improving rest and digest (parasympathetic) nerve functions, skin perfusion pressure (microcirculation) and many other changes to achieve, maintain and further improve physiological balance (homeostasis) and performance.
The three main cycles of D’OXYVA’s regimen is: Treatment, Improvement, Preventive.
D’OXYVA works especially well on mild-to-severe spider veins, varicose veins, ‘non-healing’ chronic wounds, long-term pain, severe diabetic, cardiovascular, neurological and autoimmune complications.
D’OXYVA will radically change the cost of care by 20-100X and will deliver 2-3X faster results with no prospects of patient readmission into the hospital. Pivotal trial and other studies showed 1-2 weeks pain relief, 1-2 months healing, 3-4 months amputation prevention, 6-9 months survival benefit. Studies demonstrated a prolonged progression-free result and overall survival with zero or acceptable toxicity.
Have you found anything safer and more effective? We would love to know – contact us.
Did you know? Most Frequently Administered Drugs in the U.S. Are Not What You Think!
Add these foods to increase proper blood flow.
• Onion and garlic
• Dark chocolate
• Citrus foods
• Chili powder
• Olive oil
• Nuts and seeds
These vitamins may improve circulatory health.
• Niacin
• Vitamin E
• Ascorbic acid
• Vitamin K
Moderate exercise helps to improve overall blood flow.
• Walking and jogging
• Light weightlifting
• Aerobics and yoga
• Swimming
Essential changes you can make to improve circulation.
• Stretching any time of day
• Quitting smoking
• Getting regular massages
• Resting with feet above head
• Drinking more water
Adding the D’OXYVA biotech solution to the above recommended regimen can literally transform your physical condition and mental well-being, resulting in a total enhancement of your quality of life.
D’OXYVA® (deoxyhemoglobin vasodilator) is the pioneering non-invasive biotech solution created by the health science experts at Circularity Healthcare – validated to deliver a wealth of health, athletic, and cosmetic benefits in a single pain-free, convenient, and affordable application.
Now, Circularity is seeking investment to complete its expanded pivotal trial and ramp up sales and marketing operations spanning four continents.
By our modest projections, introducing D’OXYVA into the market has a revenue potential of over $400 million dollars annually.
All stakeholders are on board with our pivotal clinical trials, while being confident in a positive outcome within a few months.
Innovative global multinationals and large hospital networks covering millions of patients are ready to procure D’OXYVA.
More information can be found in an investor presentation upon request.
We look forward to your investment to help push this product to market as fast as possible.
The finger pulse oximeter demonstrates D’OXYVA® results in under one minute. It accurately measures pulse rate, peripheral blood flow (PI), and oxygen saturation via the finger. Designed with the most straightforward operation in mind, it utilizes self-adjusting finger clips and a single-button function.
Cardiac patients and those who have circulatory pathologies will find the finger pulse oximeter to be an invaluable tool for monitoring their conditions.
*Free Finger Tip Pulse Oximeter for a limited time when you purchase D'OXYVA
Chronic Fatigue Syndrome is prevalent globally, yet it is notoriously difficult to precisely identify in the medical field, frequently leaving many individuals without clear answers. Nevertheless, recent research provides fresh optimism by uncovering the indisputable biochemical origins of chronic fatigue.
The sensation of cold hands and feet may signify more than mere discomfort; it can serve as a warning sign of underlying circulation problems that should not be disregarded. Although it is natural to overlook these symptoms as a typical reaction to lower temperatures, they often indicate that our body’s circulation is not functioning as well as it could be.
The medical community is continuously searching for innovative medical treatments to address the increasing prevalence of heart failure globally, aiming to provide hope and enhance the quality of life for patients. That said, D’OXYVA® stands out as a promising therapy for heart failure due to its use of deoxyhemoglobin vasodilator effects.
